Kerman & Co

Developing next-generation robotic system ‘Versius®’, for universal minimal access/keyhole surgery.

Equity investment in CMR Surgical's Series B funding round

Kerman & Co advised Zhejiang Silk Road Fund, a private equity fund principally sponsored and managed by Zhejiang United Investment Group, China (“ZUIG”), on its equity investment in CMR Surgical Ltd’s (“CMR Surgical”) Series B funding round.

On June 4, 2018, CMR Surgical announced that it has closed a Series B funding round raising $100 million from new investor, Zhejiang Silk Road Fund and existing investors Escala Capital Investments, LGT, Cambridge Innovation Capital and Watrium. It is thought to be Europe’s largest ever fundraising in the medical devices industry.

CMR Surgical Ltd is developing the next-generation robotic system ‘Versius®’, for universal minimal access (or “keyhole”) surgery.

http://www.kermanco.com/news/article-in-lawyer-monthly-kerman-co-advise-zhejiang-silk-road-fund-as-new-investor-in-us100-million-b-series-round-in-cmr-surgical-ltd/

Company details

Industry:
Life sciences
We are delighted to complete this transaction with the support of Kerman & Co. We relied upon Kerman for solid and sensible advice, which contributed greatly to the overall success of this investment.
James Wang Managing Partner Zhejiang United Investment Group (“ZUIG”),